Select region:

Clinical trials located in

Aalborg

Aalborg city is located in Denmark. Currently, 20 clinical trials are being conducted in this city.

Aalborg, nestled in Denmark’s North Jutland, is a vibrant city rich in Viking history. Established over 1,000 years ago, it has evolved from a bustling medieval trading post to a modern hub of culture and education. The city is renowned for its well-preserved half-timbered mansions, the 16th-century Aalborghus Castle, and the Utzon Center, showcasing the work of Jørn Utzon, the architect behind the Sydney Opera House. Aalborg’s waterfront is a testament to its industrial past, now transformed into a lively area with art and leisure facilities. The city also celebrates its heritage with the annual Aalborg Carnival, one of Scandinavia’s largest festivals.

  • CT-EU-00038810

    Advanced endometrial cancer treatment with acasunlimab and pembrolizumab

    In this trial, scientists are trying out a new treatment for advanced endometrial cancer. This treatment involves using a combination of two drugs, acasunlimab (also referred to as GEN1046) and pembrolizumab, to fight the cancer. The study aims to see how well this treatment works and what side effects might happen. Patients taking part in the trial will be divided into two groups and will be given the trial treatment for up to two years. The total time for which each patient will be monitored is about three years. The treatment’s success will be measured by counting how many patients see their cancer shrink or go away for a period of time. Doctors will be closely watching what happens from the first day of the treatment, tracking how the tumours change and noting down any unusual health happenings that could be related to the trial.

    BelgiumDenmarkSpain
  • Testing the safety and effectiveness of astegolimab for chronic lung disease

    The aim of this study is to see if a drug called astegolimab will be effective and safe in people with a lung disease called chronic obstructive pulmonary disease, or COPD. During this study, patients will be divided into 2 groups. One group of patients will receive the drug, the remaining patients will receive a placebo to compare the results. Both groups will not know what they are getting. The study was particularly interested in people suffering from COPD (chronic obstructive pulmonary disease) who smoked or still smoke and often get sick because of it.

    BelgiumDenmarkFranceGermanyNetherlandsSpainSwedenUnited Kingdom
  • Comparing treatments for new Large B-cell lymphoma patients

    The trial aims to analyze and compare two drug treatments for people who have a large B-Cell Lymphoma, a kind of cancer that affects a certain type of white blood cells, and have not yet started their treatment. The first treatment is a combination of glofitamab, polatuzumab vedotin, and other common drugs used for this condition: rituximab, cyclophosphamide, doxorubicin, and prednisone. The second treatment is the same, but doesn’t include the glofitamab. The goal is to understand which treatment is more effective and safer for the patient.

    BelgiumDenmarkFranceGermanyItalyPolandSpainUnited Kingdom
  • Testing gefurilimab treatment in patients with myasthenia gravis

    This study is looking at a potential treatment for a disease called generalized myasthenia gravis (gMG) in adults. It’s called gefurulimab (ALXN1720). For our study, researchers will divide participants into two groups, each of which will be treated differently. One group will receive the new drug. Importantly, the researchers conducting the study will not know who received which treatment. This ensures the fairness and accuracy of the results. Participants’ health will be closely monitored to ensure that ALXN1720 is safe. The main goal is to check whether new mediations are effective. It will be measured by checking whether patients’ condition has improved compared to when the study started. This will take approximately 26 weeks.

    AustriaDenmarkFranceGermanyItalyNetherlandsPolandPortugalSpainUnited Kingdom
  • Testing new treatment for Geographic Atrophy treatment

    This research study pertains to a condition affecting the eyes known as Geographic Atrophy (GA), stemming from the aging process (Age-related Macular Degeneration). The investigation aims to assess the potential efficacy of a new drug (JNJ-81201887), administered through intraocular injection, in improving the aforementioned condition. A comparative analysis will be conducted between individuals receiving the drug and those subjected to a placebo procedure (a simulated intervention lacking an actual drug). Specialized photographs will be taken to quantify any alterations in the condition over an 18-month period. Additionally, observations will be made regarding changes in distant visual acuity, reading ability, and the requirement for aids during these activities over time. Ultimately, the study will examine the impact of the eye condition on daily activities.

    BelgiumCzechiaDenmarkGermanyHungaryItalyNetherlandsPolandPortugalSpainSwedenUnited Kingdom
  • Study of alpelisib and fulvestrant for advanced breast cancer treatment

    This trial is looking at the effects of the combined use of two drugs, alpelisib and fulvestrant, in treating patients who have advanced breast cancer. The cancer should be HR-positive and HER2-negative, and have a specific mutation (PIK3CA). If the patients already underwent certain other treatments like CDK4/6 Inhibitors and aromatase Inhibitors, but the cancer has progressed, they could join this trial. Doctors will be able to compare the results of patients taking alpelisib and fulvestrant together, with those taking fulvestrant with a placebo, They aim to check which combination works better in delaying the advance of cancer or in improving a patient’s life duration.

    BelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyPolandPortugalRomaniaSlovakiaSpain
  • Testing new medicine for children’s migraine relief

    This study is a test to see how safe and effective a medicine called Atogepant is when given to children and teenagers (6 to 17 years old) who get migraines. Migraines are bad headaches that can make feel sick or sensitive to light and sound. Atogepant is a tablet that is already approved for adults who get migraines, and now the researchers want to see how it works for younger people. The patients will be divided into six groups, which will be given either a placebo, a low-dose Atogepant, or a high-dose Atogepant. This will continue for 12 weeks. After this, there may be further follow-up visits or another study where the patients can continue to take the Atogepant. Testing during the study will include doctor’s visits, blood tests, questionnaires and checking for any side effects.

    DenmarkFranceHungaryItalyNetherlandsPolandSpainSwedenUnited Kingdom
  • Testing Nipocalimab’s effect on adults with Muscle Weakness

    This study is about a new drug called nipocalimab for patients with a disease called Myasthenia Gravis (MG). MG patients feel weak in their muscles, and nipocalimab potentially could help to lessen this weakness. The drug functions by attaching itself to certain components of the blood to lessen the reaction causing muscle weakness. This large-scale study will take place in multiple hospitals and is organized in different phases including initial checks (4 weeks), treatment (24 weeks) and follow-ups (up to 2 years). It will be measured how well the treatment works through daily activity scores and strength tests.

    BelgiumCzechiaDenmarkFranceGermanyItalyPolandSpainSweden
  • Study on new medicine’s effect and safety in short bowel syndrome treatment

    This trial is designed to check how safe and effective a drug named HM15912 is for people suffering from severe bowel problems, a condition known as short bowel syndrome (SBS). Some patients will get the real drug, while others get placebo – and nobody will know who will get what. The doctors then will check how these injections of HM15912 impact your health, how your body processes the drug, and how the drug affects your body’s functions. The entire process will extend over a period of about 13 months, along with a safety follow-up period.

    BelgiumDenmarkFranceGermanyPoland
  • Testing navitoclax and ruxolitinib effective on myelofibrosis patients

    This study is trying to find out if the combination of two drugs called Navitoclax and Ruxolitinib can help people with a type of blood cancer called Myelofibrosis. Around 330 adults, who have myelofibrosis that hasn’t responded to previous treatments, will get either the new drug combination or the current best treatment for their disease. Doctors will measure whether the new combination is more effective by checking how much the size of participants’ spleens have changed during the study with scans, measuring fatigue levels and checking how well their bone marrow works.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyPolandSpainSwedenUnited Kingdom
  • Study on a new combination therapy for active ulcerative colitis

    This study aims to assess the effectiveness and safety of new combination therapy with JNJ-78934804 (Guselkumab/Golimumab) in comparison to guselkumab and golimumab administred alone for individuals with moderately to severely active ulcerative colitis. Participants who have shown inadequate response, loss of response, or intolerance to approved advanced therapies will be included. The trial includes various treatment groups: placebo, Guselkumab, Golimumab, and different doses of JNJ-78934804. All participants meeting inadequate response criteria will be escalated to an active treatment. The study will last for 48 weeks and the progress will be tracked over this period. The primary focus is to evaluate the efficacy and safety of the different doses of new therapy in managing ulcerative colitis over the course of the study.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalSlovakiaSloveniaSpainSwedenUnited Kingdom
  • Testing mavacamten for heart muscle disease

    This study aims to assess a drug called Mavacamten for a heart condition called Non-Obstructive Hypertrophic Cardiomyopathy. Patients will be randomly given either the actual drug or a placebo without anyone knowing which one they’ve received. The study will measure how safe and effective the drug is for patients with symptoms of this heart condition. The success of the drug will be determined by preventing heart-related issues such as heart attacks, strokes, heart failures, irregular heartbeats, and the need for a heart-rhythm controlling device.

    AustriaBelgiumCzechiaDenmarkFranceGermanyHungaryItalyNetherlandsNorwayPolandPortugalSpainUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Assessing olpasiran treatment for heart disease and elevated cholesterol

    Tests named ‘OCEAN(a)’ are being conducted, focusing on a medication called ‘olpasiran’. Put simply, the potential of this medication in preventing serious heart episodes in individuals with Atherosclerotic Cardiovascular Disease and an elevated level of a fat protein, Lipoprotein(a), is under examination. The effect of a harmless, dummy pill (placebo) is compared to that of the actual medication, olpasiran, in individuals with these conditions. The primary goal is to determine whether olpasiran can reduce the risk of death due to heart disease, occurrence of heart attacks, or the necessity for sudden surgery to clear blocked heart vessels.

    AustriaBelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalRomaniaSlovakiaSpainSwedenUnited Kingdom
  • Testing drug combinations in recurring multiple myeloma

    This is a type of research study where the researchers compare two different treatments for multiple myeloma, a type of cancer in your blood. In the study, people will be placed into different groups and receive either a combination of iberdomide, daratumumab, and dexamethasone, or another combination of daratumumab, bortezomib, and dexamethasone. The researchers want to check how well the cancer responds to these treatments and see which one works better.

    AustriaBelgiumCzechiaDenmarkFinlandFranceGermanyGreeceItalyNetherlandsNorwayPolandPortugalSpainSwedenUnited Kingdom
  • Impact of apalutamide on hormone-sensitive prostate cancer

    This is a study on prostate cancer, particularly patients suffering from a high-risk, hormone-sensitive form. The researchers want to check how adding a drug called apalutamide to the regular treatment can affect the cancer. The standard treatment includes radiotherapy and a drug that blocks the hormone responsible for cancer growth, known as LHRH. This study will check if adding apalutamide can delay the cancer from spreading or help patients live longer. The researchers will track disease progress using a special imaging test called PSMA-PET. They will also monitor changes in PSA, a protein made by the prostate that rises when cancer is present. Other important measures include how long it takes for the cancer to spread and the general rate of survival.

    AustriaBelgiumCzechiaDenmarkFinlandGermanyHungaryItalyPolandPortugalSlovakiaSpainSweden
  • Testing the efficacy of teclistamab vs other drugs for relapsed or refractory multiple myeloma treatment

    The study is evaluating a treatment for a blood cancer known as multiple myeloma. Two different treatments are being compared to assess their effectiveness in both slowing down the disease and minimizing side effects. The first treatment involves a single medicine called teclistamab, while the second offers a choice between two combinations of multiple medicines (either PVd – pomalidomide, bortezomib, dexamethasone or Kd – carfilzomib, dexamethasone). Both treatments have been previously administered to individuals with similar conditions. Individuals who have undergone prior treatment, including the use of an anti-CD38 monoclonal antibody and lenalidomide, but experienced a recurrence or lack of resolution of the disease, are eligible to participate in this study. The objective is to determine the duration it takes for the disease to progress under different treatments. Additionally, the study will monitor changes in health and potential medication-related issues through regular check-ups.

    AustriaBelgiumCzechiaDenmarkFranceGermanyGreeceItalyNetherlandsPolandPortugalSpainSwedenUnited Kingdom
  • Evaluating treatment strategies for small-cell lung cancer: A clinical trial with lurbinectedin, irinotecan, and topotecan

    This is a large test the researchers are running to help people with a certain type of lung cancer (called Small-cell Lung Cancer) that’s come back after they’ve had one type of treatment that contains platinum. The researchers are using three different ways of giving medicine to see which is best. The first way is to give only lurbinectedin. The second way is to give lurbinectedin and irinotecan together. The third way is to let the doctor decide to use topotecan or irinotecan alone. People’s selection to these groups will be by chance.

    AustriaBelgiumBulgariaDenmarkFranceGermanyHungaryItalyPolandRomaniaSpainUnited Kingdom
  • Inhaler treatment study for Mycobacterium Avium complex lung infection

    This study is for adults with lung infections caused by Mycobacterium avium complex. It tests a new inhalation treatment, ALIS (amikacin liposome inhalation suspension), in combination with standard drugs, azithromycin and ethambutol. The aim is to see if ALIS improves respiratory symptoms better than the standard treatment alone. Participants will receive either ALIS or a placebo, along with the standard drugs. The study focuses on safety, symptom improvement, and overall health impact. This research is important for finding more effective treatments for these challenging lung infections.

    AustriaBelgiumDenmarkFranceGermanyGreeceHungaryItalyPolandPortugalSpainUnited Kingdom

See more clinical trials in other cities in Denmark:

.